Organon & Co.

For the period ended Jun 30, 2026. Filed Jul 31, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 31, 2026

OGN$13.85-0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Product and Geographic Information

Product and Geographic Information

Revenues of the Company’s products were as follows:

Three Months Ended June 30, · Six Months Ended June 30,
	2026			2025			2026			2025
($ in millions)	U.S.	Int’l	Total	U.S.	Int’l	Total	U.S.	Int’l	Total	U.S.	Int’l	Total
Women’s Health
Nexplanon/Implanon NXT	$129	$101	$230	$163	$77	$240	$256	$175	$431	$339	$148	$488
Follistim AQ	17	43	59	30	43	74	38	82	120	65	77	142
NuvaRing	9	18	27	7	21	28	14	37	51	13	37	50
Ganirelix Acetate Injection	2	24	26	3	25	27	4	48	52	7	47	54
Marvelon/Mercilon	—	32	32	—	33	33	—	58	58	—	72	72
Jada (3)	—	—	—	18	—	18	5	—	5	33	—	33
Other Women’s Health (1)	15	29	45	14	27	42	33	58	90	30	57	86
General Medicines
Biosimilars
Renflexis	44	21	65	46	17	63	87	36	122	90	30	120
Hadlima	55	24	79	36	14	50	106	40	146	69	27	96
Ontruzant	5	1	6	5	26	31	9	2	11	8	41	49
Brenzys	—	14	14	—	22	22	—	34	34	—	36	36
Bildyos/Bilprevda	14	5	19	—	—	—	20	15	35	—	—	—
Other Biosimilars (1)	10	2	12	3	4	7	15	5	20	3	10	13
Established Brands
Cardiovascular
Atozet	—	80	80	—	86	86	—	165	165	—	162	162
Zetia	2	95	96	1	72	74	3	181	183	3	156	159
Cozaar/Hyzaar	2	48	50	2	54	56	5	103	107	4	107	111
Vytorin	1	20	21	1	26	27	2	40	42	2	48	50
Rosuzet	—	5	5	—	6	6	—	11	11	—	10	10
Other Cardiovascular (1)	1	23	25	1	33	34	1	50	53	1	64	65
Respiratory
Singulair	2	46	48	2	64	66	4	84	88	4	136	140
Nasonex	—	58	58	—	66	66	—	123	123	—	137	137
Dulera	30	11	41	32	9	41	53	23	76	66	19	84
Clarinex	1	30	30	1	33	34	2	60	61	1	67	68
Other Respiratory (1)	16	1	18	11	3	14	27	3	30	21	6	27
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—	69	69	—	63	63	—	128	128	—	124	124
Fosamax	1	24	25	—	34	34	1	53	54	2	65	67
Diprospan	—	44	44	—	41	41	—	79	79	—	71	71
Vtama	34	1	35	29	2	31	57	3	60	49	6	54
Other Non-Opioid Pain, Bone and Dermatology (1)	4	75	79	4	76	80	7	140	147	7	143	151
Other
Propecia	2	34	36	1	30	32	3	62	65	3	55	58
Emgality	—	54	54	—	42	42	—	108	108	—	74	74
Proscar	—	20	20	—	22	22	—	46	46	—	46	46
Other (1)	2	94	96	3	85	87	4	178	184	5	159	164
Other (2)	—	14	14	1	24	23	—	32	33	1	44	46
Revenues	$398	$1,160	$1,558	$414	$1,180	$1,594	$756	$2,262	$3,018	$826	$2,281	$3,107

Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies unless otherwise indicated.

(1) Includes sales of products not listed separately.

(2) Includes manufacturing sales to third parties.

(3)Jada is a trademark registered in the US in the name of Alydia Health, Inc.

-12-

Revenues by geographic area where derived are as follows:

	Three Months EndedJune 30,		Six Months EndedJune 30,
($ in millions)	2026	2025	2026	2025
Europe and Canada	$432	$419	$845	$795
United States	398	414	756	826
Asia Pacific and Japan	232	250	457	502
China	208	204	402	409
Latin America, Middle East, Russia, and Africa	269	285	516	524
Other (1)	19	22	42	51
Revenues	$1,558	$1,594	$3,018	$3,107

(1) Includes manufacturing sales to third parties.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.